Our paper has been published in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. Mario A Parra MD PhD, Juan Granada MD, gerardo fernandez PhD, et al. (2022). In a 40-month prospective study, ViewMind showed:
Highlights:
• Ability to very accurately differentiate cognitive decline due to aging versus a dementia
• 100% correlation between the prospective prediction and an independent clinical diagnosis (blinded)
• Biomarker is based on ocular movements and AI and works independently of culture, age, and education
Related Posts
Scarlett Chen from Verge HealthTech Fund joins ViewMind’s board of directors
ViewMind today announced Scarlett Sijia Chen, Managing Partner of Verge HealthTech Fund, has been elected to ViewMind’s board of directors. Scarlett brings decades of experience…
Memory-driven eye movements prospectively predict dementia in people at risk of Alzheimer’s disease
Oculomotor behaviors linked to cognitive performance revealed neurocognitive features of Alzheimer’s disease (AD) that can enhance the accuracy of its assessment and diagnosis
ViewMind Applauded by Frost & Sullivan for Its One-of-a-kind Digital Biomarker Technology for Neurocognitive Disorders
ViewMind Applauded by Frost & Sullivan for Its One-of-a-kind Digital Biomarker Technology for Neurocognitive Disorders Homepage >> Press Releases >> ViewMind Applauded by Frost & Sullivan for Its
